{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:44:09Z","timestamp":1792827849040,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["T32 HL007853"],"award-info":[{"award-number":["T32 HL007853"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIGMS","doi-asserted-by":"publisher","award":["GM131835"],"award-info":[{"award-number":["GM131835"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIGMS","doi-asserted-by":"publisher","award":["GM140223"],"award-info":[{"award-number":["GM140223"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["23PRE1019986"],"award-info":[{"award-number":["23PRE1019986"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jtha.2023.09.013","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T15:22:59Z","timestamp":1700666579000},"page":"3317-3328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Antiplatelet strategies: past, present, and future"],"prefix":"10.1016","volume":"21","author":[{"given":"Livia","family":"Stanger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Holinstat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.09.013_bib1","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics-2023 update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2023.09.013_bib2","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1161\/STROKEAHA.120.028992","article-title":"Risk and secondary prevention of stroke recurrence: a population-base cohort study","volume":"51","author":"Flach","year":"2020","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2023.09.013_bib3","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1161\/CIRCULATIONAHA.120.047065","article-title":"Trends in recurrent coronary heart disease after myocardial infarction among US women and men between 2008 and 2017","volume":"143","author":"Peters","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2023.09.013_bib4","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/17512433.2022.2121702","article-title":"Clinical pharmacology of antiplatelet drugs","volume":"15","author":"Gelbenegger","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jtha.2023.09.013_bib5","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41569-021-00552-1","article-title":"Interplay between inflammation and thrombosis in cardiovascular pathology","volume":"18","author":"Stark","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jtha.2023.09.013_bib6","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bjh.14520","article-title":"The aspirin story - from willow to wonder drug","volume":"177","author":"Desborough","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2023.09.013_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bph.15966","article-title":"Fifty years with aspirin and platelets","volume":"180","author":"Patrono","year":"2023","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jtha.2023.09.013_bib8","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1136\/ard.23.6.500","article-title":"Influence of aspirin on haemostatic parameters","volume":"23","author":"Gast","year":"1964","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jtha.2023.09.013_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2018.10.008","article-title":"The first 3500 years of aspirin history from its roots - A concise summary","volume":"113","author":"Montinari","year":"2019","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.jtha.2023.09.013_bib10","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2023.09.013_bib11","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2102137","article-title":"Comparative effectiveness of aspirin dosing in cardiovascular disease","volume":"384","author":"Jones","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jtha.2023.09.013_bib12","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1160\/TH12-07-0532","article-title":"High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs--pharmacological mechanisms and clinical relevance","volume":"109","author":"Hohlfeld","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.09.013_bib13","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.jacc.2018.02.036","article-title":"Effect of aspirin coadministration on the safety of celecoxib, naproxen, or ibuprofen","volume":"71","author":"Reed","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2023.09.013_bib14","doi-asserted-by":"crossref","first-page":"394","DOI":"10.7326\/0003-4819-129-5-199809010-00009","article-title":"The antiplatelet effects of ticlopidine and clopidogrel","volume":"129","author":"Sharis","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2023.09.013_bib15","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1177\/106002809302700915","article-title":"Ticlopidine and antiplatelet therapy","volume":"27","author":"Flores-Runk","year":"1993","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jtha.2023.09.013_bib16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.crci.2012.05.006","article-title":"The story of clopidogrel and its predecessor, ticlopidine: could these major antiplatelet and antithrombotic drugs be discovered and developed today?","volume":"15","author":"Maffrand","year":"2012","journal-title":"Comptes Rendus Chimie"},{"key":"10.1016\/j.jtha.2023.09.013_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41569-023-00854-6","article-title":"Current concepts and novel targets for antiplatelet therapy","author":"Gawaz","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jtha.2023.09.013_bib18","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/cpt.2526","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update","volume":"112","author":"Lee","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jtha.2023.09.013_bib19","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.09.013_bib20","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.09.013_bib21","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2023.09.013_bib22","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1527-3466.2007.00027.x","article-title":"Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile","volume":"25","author":"Jakubowski","year":"2007","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.jtha.2023.09.013_bib23","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10557-021-07202-1","article-title":"Efficacy and safety of low-dose prasugrel versus clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"36","author":"Wongsalap","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jtha.2023.09.013_bib24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/CRD.0000000000000181","article-title":"Switching from ticagrelor or prasugrel to clopidogrel","volume":"26","author":"Nawarskas","year":"2018","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.jtha.2023.09.013_bib25","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pharmthera.2016.01.004","article-title":"Current status of data on cangrelor","volume":"159","author":"Qamar","year":"2016","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jtha.2023.09.013_bib26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.resuscitation.2019.02.008","article-title":"Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y(12) inhibition from the IABP-SHOCK II trial","volume":"137","author":"Droppa","year":"2019","journal-title":"Resuscitation"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2023.09.013_bib27","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.amjcard.2020.12.020","article-title":"Dual antiplatelet therapy de-escalation strategies","volume":"144","author":"Sinnaeve","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jtha.2023.09.013_bib28","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2023.09.013_bib29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40292-023-00562-9","article-title":"An updated review on glycoprotein IIb\/IIIa inhibitors as antiplatelet agents: basic and clinical perspectives","volume":"30","author":"Sharifi-Rad","year":"2023","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"10.1016\/j.jtha.2023.09.013_bib30","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/01.CIR.98.8.734","article-title":"Randomized, placebo-controlled trial of platelet glycoprotein IIb\/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators","volume":"98","author":"Brener","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2023.09.013_bib31","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1365-2125.2010.03879.x","article-title":"Anti-platelet therapy: glycoprotein IIb-IIIa antagonists","volume":"72","author":"Schneider","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2023.09.013_bib32","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2023.09.013_bib33","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1161\/CIRCRESAHA.112.300570","article-title":"Integrin \u03b1IIb\u03b23: from discovery to efficacious therapeutic target","volume":"112","author":"Bledzka","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.jtha.2023.09.013_bib34","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.120.046928","article-title":"Cangrelor, tirofiban, and chewed or standard prasugrel regimens in patients with ST-segment-elevation myocardial infarction: primary results of the FABOLUS-FASTER trial","volume":"142","author":"Gargiulo","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2023.09.013_bib35","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes","volume":"339","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.09.013_bib36","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2125.2011.04034.x","article-title":"Anti-platelet therapy: phosphodiesterase inhibitors","volume":"72","author":"Gresele","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2023.09.013_bib37","doi-asserted-by":"crossref","first-page":"47581","DOI":"10.1074\/jbc.M206088200","article-title":"Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity","volume":"277","author":"Francis","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2023.09.013_bib38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/978-3-642-29423-5_9","article-title":"Targeting phosphodiesterases in antiplatelet therapy","author":"Rondina","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.jtha.2023.09.013_bib39","first-page":"404","article-title":"Cilostazol approved for use in intermittent claudication","volume":"56","author":"Miller","year":"1999","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jtha.2023.09.013_bib40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00002512-199914010-00005","volume":"14","author":"Sorkin","year":"1999","journal-title":"Cilostazol. Drugs Aging"},{"key":"10.1016\/j.jtha.2023.09.013_bib41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atherosclerosissup.2005.09.002","article-title":"Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding","volume":"6","author":"Goto","year":"2005","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.jtha.2023.09.013_bib42","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1161\/STROKEAHA.120.029454","article-title":"Cilostazol for secondary prevention of stroke and cognitive decline: systematic review and meta-analysis","volume":"51","author":"McHutchison","year":"2020","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2023.09.013_bib43","article-title":"Small but steady steps in stroke medicine in Japan","volume":"8","author":"Toyoda","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jtha.2023.09.013_bib44","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1474-4422(19)30148-6","article-title":"Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial","volume":"18","author":"Toyoda","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2023.09.013_bib45","article-title":"Acute aspirin plus cilostazol dual therapy for noncardioembolic stroke patients within 48 hours of symptom onset","volume":"8","author":"Aoki","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jtha.2023.09.013_bib46","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1161\/STROKEAHA.121.035002","article-title":"Cilostazol for secondary stroke prevention: history, evidence, limitations, and possibilities","volume":"52","author":"de Havenon","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2023.09.013_bib47","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2023.09.013_bib48","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJMoa0805002","article-title":"Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke","volume":"359","author":"Sacco","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.09.013_bib49","doi-asserted-by":"crossref","first-page":"3c","DOI":"10.1016\/S0002-9149(99)00042-9","article-title":"Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in\u00a0vitro","volume":"83","author":"Wallis","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jtha.2023.09.013_bib50","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00005344-200104000-00008","article-title":"Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil","volume":"37","author":"Berkels","year":"2001","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jtha.2023.09.013_bib51","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1177\/0003319710362977","article-title":"Effects of tadalafil on platelets and endothelium in patients with erectile dysfunction and cardiovascular risk factors: a pilot study","volume":"61","author":"De Bon","year":"2010","journal-title":"Angiology"},{"key":"10.1016\/j.jtha.2023.09.013_bib52","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s40265-014-0252-2","article-title":"Vorapaxar: first global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.jtha.2023.09.013_bib53","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.09.013_bib54","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0031-6997(24)01493-5","article-title":"Proteinase-activated receptors","volume":"53","author":"Macfarlane","year":"2001","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jtha.2023.09.013_bib55","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1586\/14779072.2015.1109447","article-title":"Vorapaxar in the secondary prevention of atherothrombosis","volume":"13","author":"Tantry","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jtha.2023.09.013_bib56","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.ahj.2014.09.002","article-title":"Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial","volume":"168","author":"Tricoci","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.jtha.2023.09.013_bib57","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/nm.3385","article-title":"Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c","volume":"19","author":"Edelstein","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2023.09.013_bib58","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1021\/bi00177a018","article-title":"Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes","volume":"33","author":"Mathews","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.jtha.2023.09.013_bib59","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1042\/bj20030954","article-title":"Protease-activated receptor-4 uses dual prolines and an anionic retention motif for thrombin recognition and cleavage","volume":"376","author":"Jacques","year":"2003","journal-title":"Biochem J"},{"key":"10.1016\/j.jtha.2023.09.013_bib60","doi-asserted-by":"crossref","first-page":"8843","DOI":"10.1021\/acs.jmedchem.2c00359","article-title":"Discovery of two novel antiplatelet clinical candidates (BMS-986120 and BMS-986141) that antagonize protease-activated receptor 4","volume":"65","author":"Priestley","year":"2022","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jtha.2023.09.013_bib61","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1080\/09537104.2022.2088719","article-title":"New oral protease-activated receptor 4 antagonist BMS-986120: tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans","volume":"33","author":"Merali","year":"2022","journal-title":"Platelets"},{"key":"10.1016\/j.jtha.2023.09.013_bib62","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1055\/s-0037-1614928","article-title":"Molecular analyses of the platelet glycoprotein Ib-IX-V receptor","volume":"79","author":"Ware","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.09.013_bib63","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.3389\/fimmu.2019.02884","article-title":"von Willebrand factor and platelet glycoprotein Ib: a thromboinflammatory axis in stroke","volume":"10","author":"Denorme","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2023.09.013_bib64","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1160\/TH13-06-0490","article-title":"Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in\u00a0vitro and in\u00a0vivo in murine models of thrombosis","volume":"111","author":"Lei","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.09.013_bib65","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1160\/TH14-03-0217","article-title":"Glycoprotein Ibalpha clustering induces macrophage-mediated platelet clearance in the liver","volume":"113","author":"Yan","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.09.013_bib66","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1038\/ncomms8737","article-title":"Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia","volume":"6","author":"Li","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtha.2023.09.013_bib67","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1182\/bloodadvances.2016000711","article-title":"Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura","volume":"1","author":"Zheng","year":"2016","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.09.013_bib68","article-title":"In\u00a0vitro assessment and phase I randomized clinical trial of anfibatide a snake venom derived anti-thrombotic agent targeting human platelet GPIbalpha","volume":"11","author":"Li","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtha.2023.09.013_bib69","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/phar.2620","article-title":"Safety and efficacy of a platelet glycoprotein Ib inhibitor for patients with non-ST segment elevation myocardial infarction: A phase Ib\/IIa study","volume":"41","author":"Zheng","year":"2021","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jtha.2023.09.013_bib70","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.2515","article-title":"Arterial thrombosis--insidious, unpredictable and deadly","volume":"17","author":"Jackson","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2023.09.013_bib71","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1096\/fj.03-0464fje","article-title":"Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in\u00a0vivo","volume":"18","author":"Massberg","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.jtha.2023.09.013_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100592","article-title":"Clinical significance of altered collagen-receptor functioning in platelets with emphasis on glycoprotein VI","volume":"38","author":"Nurden","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2023.09.013_bib73","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.110.980623","article-title":"Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans","volume":"123","author":"Ungerer","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2023.09.013_bib74","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1161\/STROKEAHA.122.039790","article-title":"Glenzocimab: A GPVI (Glycoprotein VI)-targeted potential antiplatelet agent for the treatment of acute ischemic stroke","volume":"53","author":"Wichaiyo","year":"2022","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2023.09.013_bib75","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1161\/ATVBAHA.118.312314","article-title":"Safety and tolerability, pharmacokinetics, and pharmacodynamics of ACT017, an antiplatelet GPVI (Glycoprotein VI) Fab","volume":"39","author":"Voors-Pette","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2023.09.013_bib76","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1016\/j.jtha.2023.07.018","article-title":"Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy","volume":"21","author":"Alenazy","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.09.013_bib77","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1161\/ATVBAHA.120.315154","article-title":"Lipid receptor GPR31 (G-Protein-Coupled Receptor 31) regulates platelet reactivity and thrombosis without affecting hemostasis","volume":"41","author":"Van Doren","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2023.09.013_bib78","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1016\/j.bmc.2006.01.057","article-title":"Baicalein is a potent in\u00a0vitro inhibitor against both reticulocyte 15-human and platelet 12-human lipoxygenases","volume":"14","author":"Deschamps","year":"2006","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.jtha.2023.09.013_bib79","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/sj.bjp.0702976","article-title":"An anti-platelet agent, OPC-29030, inhibits translocation of 12-lipoxygenase and 12-hydroxyeicosatetraenoic acid production in human platelets","volume":"128","author":"Ozeki","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jtha.2023.09.013_bib80","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0014-2999(01)00924-4","article-title":"5-Lipoxygenase is required for proliferation of immature cerebellar granule neurons in\u00a0vitro","volume":"418","author":"Uz","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jtha.2023.09.013_bib81","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0262-1746(84)90102-1","article-title":"Comparative effects of indomethacin, acetylenic acids, 15-HETE, nordihydroguaiaretic acid and BW755C on the metabolism of arachidonic acid in human leukocytes and platelets","volume":"13","author":"Salari","year":"1984","journal-title":"Prostaglandins Leukot Med"},{"key":"10.1016\/j.jtha.2023.09.013_bib82","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023020441","article-title":"Cryo-EM structures of human arachidonate 12S-Lipoxygenase (12-LOX) bound to endogenous and exogenous inhibitors","author":"Mobbs","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.09.013_bib83","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1161\/ATVBAHA.117.309868","article-title":"First selective 12-LOX inhibitor, ML355, impairs thrombus formation and vessel occlusion in\u00a0vivo with minimal effects on hemostasis","volume":"37","author":"Adili","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2023.09.013_bib84","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2014-05-575878","article-title":"Platelet 12-LOX is essential for FcgammaRIIa-mediated platelet activation","volume":"124","author":"Yeung","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.09.013_bib85","doi-asserted-by":"crossref","DOI":"10.1161\/ATVBAHA.123.319434","article-title":"Novel strategy to combat the procoagulant phenotype in heparin-induced thrombocytopenia using 12-LOX inhibition","author":"Renna","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2023.09.013_bib86","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1164\/ajrccm.159.6.9804054","article-title":"Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension","volume":"159","author":"Tuder","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jtha.2023.09.013_bib87","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0055-2016","article-title":"Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience","volume":"26","author":"Sitbon","year":"2017","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jtha.2023.09.013_bib88","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00005344-200302000-00019","article-title":"Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension","volume":"41","author":"McLaughlin","year":"2003","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jtha.2023.09.013_bib89","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/hrt.80.2.151","article-title":"Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension","volume":"80","author":"Higenbottam","year":"1998","journal-title":"Heart"},{"key":"10.1016\/j.jtha.2023.09.013_bib90","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0140-6736(97)24019-5","article-title":"Orally active prostacyclin analogue in primary pulmonary hypertension","volume":"349","author":"Okano","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2023.09.013_bib91","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1016\/j.bmc.2007.08.010","article-title":"Structure-activity studies on diphenylpyrazine derivatives: a novel class of prostacyclin receptor agonists","volume":"15","author":"Asaki","year":"2007","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.jtha.2023.09.013_bib92","doi-asserted-by":"crossref","first-page":"7128","DOI":"10.1021\/acs.jmedchem.5b00698","article-title":"Selexipag: an oral and selective ip prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"58","author":"Asaki","year":"2015","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jtha.2023.09.013_bib93","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1021\/acs.jmedchem.6b00871","article-title":"Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): an orally active prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"60","author":"Tran","year":"2017","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jtha.2023.09.013_bib94","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1161\/ATVBAHA.116.308050","article-title":"12(S)-HETrE, a 12-lipoxygenase oxylipin of dihomo-gamma-linolenic acid, inhibits thrombosis via Galphas signaling in platelets","volume":"36","author":"Yeung","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2023.09.013_bib95","doi-asserted-by":"crossref","unstructured":"Stanger L, Yamaguchi A, Yalavarthi P, Lambert S, Gilmore D, Rickenberg A, Luke C, Kumar K, Obi AT, White A, Bergh N, Dahlof BL, Holinstat M. The oxylipin analogue CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptor. Blood 2023;blood.2023020622.","DOI":"10.1182\/blood.2023020622"},{"key":"10.1016\/j.jtha.2023.09.013_bib96","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2174\/187152511797037619","article-title":"12-lipoxygenase: a potential target for novel anti-platelet therapeutics","volume":"9","author":"Yeung","year":"2011","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"10.1016\/j.jtha.2023.09.013_bib97","doi-asserted-by":"crossref","first-page":"28275","DOI":"10.1073\/pnas.2008921117","article-title":"GPR56\/ADGRG1 is a platelet collagen-responsive GPCR and hemostatic sensor of shear force","volume":"117","author":"Yeung","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2023.09.013_bib98","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1096\/fj.05-4395fje","article-title":"Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta","volume":"20","author":"Ali","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.jtha.2023.09.013_bib99","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1182\/bloodadvances.2020002493","article-title":"Omega-6 DPA and its 12-lipoxygenase-oxidized lipids regulate platelet reactivity in a nongenomic PPARalpha-dependent manner","volume":"4","author":"Yeung","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.09.013_bib100","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911317","article-title":"Aspirin resistance in vascular disease: a review highlighting the critical need for improved point-of-care testing and personalized therapy","volume":"23","author":"Khan","year":"2022","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623007158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623007158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:40:32Z","timestamp":1761536432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623007158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":100,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1538783623007158"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.09.013","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiplatelet strategies: past, present, and future","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}